Patents by Inventor Mark Millan
Mark Millan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120309838Abstract: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of Obsessive-Compulsive Disorder (OCD).Type: ApplicationFiled: February 10, 2011Publication date: December 6, 2012Applicant: Les Laboratoires ServierInventors: Laurence Laigle, Elisabeth Mocaer, Mark Millan
-
Patent number: 8247441Abstract: The invention relates to compounds of formula (I): wherein R1 and R2 together form the following carbon-containing chain: wherein: R3 represents a hydrogen atom or an alkyl group, R4 represents a hydrogen atom or an alkyl, aryl, heteroaryl, 3,4-dioxocyclobutenyl, alkylcarbonyl, cycloalkylcarbonyl, heterocycloalkylcarbonyl, benzoyl, arylsulphonyl or heteroarylsulphonyl group, each of those groups optionally being substituted, or R3 and R4 together with the nitrogen atom carrying them form a 5- to 8-membered ring, the ring thereby formed optionally being substituted. Medicinal products containing the same which are useful in treating conditions requiring a D3 receptor antagonist.Type: GrantFiled: July 20, 2010Date of Patent: August 21, 2012Assignee: Les Laboratoires ServierInventors: Guillaume De Nanteuil, Bernard Cimetiere, Anne Dekeyne, Mark Millan
-
Patent number: 7960438Abstract: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of Generalized Anxiety Disorder.Type: GrantFiled: April 4, 2007Date of Patent: June 14, 2011Assignee: Les Laboratoires ServierInventors: Bruno Delalleau, Agnes Fabiano, Mark Millan, Elisabeth Mocaer
-
Patent number: 7947852Abstract: Compounds of formula (I): wherein: R1 represents alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, X represents a group N—OR2 wherein R2 represents a hydrogen atom or an alkyl group. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.Type: GrantFiled: July 1, 2008Date of Patent: May 24, 2011Assignee: Les Laboratoires ServierInventors: Said Yous, Mohamed Ettaoussi, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
-
Publication number: 20110021490Abstract: The invention relates to compounds of formula (I): wherein R1 and R2 together form the following carbon-containing chain: wherein: R3 represents a hydrogen atom or an alkyl group, R4 represents a hydrogen atom or an alkyl, aryl, heteroaryl, 3,4-dioxocyclobutenyl, alkylcarbonyl, cycloalkylcarbonyl, heterocycloalkylcarbonyl, benzoyl, arylsulphonyl or heteroarylsulphonyl group, each of those groups optionally being substituted, or R3 and R4 together with the nitrogen atom carrying them form a 5- to 8-membered ring, the ring thereby formed optionally being substituted. Medicinal products containing the same which are useful in treating conditions requiring a D3 receptor antagonist.Type: ApplicationFiled: July 20, 2010Publication date: January 27, 2011Applicant: LES LABORATOIRES SERVIERInventors: Guillaume De Nanteuil, Bernard Cimetiere, Anne Dekeyne, Mark Millan
-
Publication number: 20100168244Abstract: Compounds of formula (I): wherein: R1 represents alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, X represents a group N—OR2 wherein R2 represents a hydrogen atom or an alkyl group. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.Type: ApplicationFiled: July 1, 2008Publication date: July 1, 2010Applicant: LESS LABORATOIRES SERVIERInventors: Said Yous, Mohamed Ettaoussi, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
-
Publication number: 20100137446Abstract: Compounds of formula (I): wherein: R1 represents alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, R2 represents a fluorine atom or an alkyl group substituted by one or more fluorine atoms. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.Type: ApplicationFiled: July 1, 2008Publication date: June 3, 2010Inventors: Said Yous, Mohamed Ettaoussi, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
-
Patent number: 7612061Abstract: A compound selected from those of formula (I): wherein: R1, R2, R3 and R4, which may be the same or different, each represent an atom or group selected from hydrogen, halogen, alkyl, alkoxy, phenyl and cyano, X represents a bond, an oxygen atom or a group selected from —(CH2)m—, —OCH2— and —NR5—, wherein m represents 1 or 2, and R5 is as defined in the description, Y represents an oxygen atom or a group selected from NR7 and CHR8, wherein R7 and R8 are as defined in the description, Z represents a nitrogen atom or a CH group, n represents 1 or 2, Ak represents an alkylene chain, Ar represents an aryl or heteroaryl group, its optical isomers, and addition salts thereof with a pharmaceutically acceptable acid. Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK1 antagonist.Type: GrantFiled: November 10, 2008Date of Patent: November 3, 2009Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Aimee Dessinges, Bertrand Goument, Mark Millan, Clotilde Mannoury La Cour
-
Publication number: 20090075982Abstract: A compound selected from those of formula (I): wherein: R1, R2, R3 and R4, which may be the same or different, each represent an atom or group selected from hydrogen, halogen, alkyl, alkoxy, phenyl and cyano, X represents a bond, an oxygen atom or a group selected from —(CH2)m—, —OCH2— and —NR5—, wherein m represents 1 or 2, and R5 is as defined in the description, Y represents an oxygen atom or a group selected from NR7 and CHR8, wherein R7 and R8 are as defined in the description, Z represents a nitrogen atom or a CH group, n represents 1 or 2, Ak represents an alkylene chain, Ar represents an aryl or heteroaryl group, its optical isomers, and addition salts thereof with a pharmaceutically acceptable acid. Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK1 antagonist.Type: ApplicationFiled: November 12, 2008Publication date: March 19, 2009Applicant: LES LABORATOIRES SERVIERInventors: Jean-Louis Peglion, Aimee Dessinges, Bertrand Goument, Mark Millan, Clotilde Mannoury La Cour
-
Publication number: 20090076030Abstract: A compound selected from those of formula (I): wherein: R1, R2, R3 and R4, which may be the same or different, each represent an atom or group selected from hydrogen, halogen, alkyl, alkoxy, phenyl and cyano, X represents a bond, an oxygen atom or a group selected from —(CH2)m—, —OCH2— and —NR5—, wherein m represents 1 or 2, and R5 is as defined in the description, Y represents an oxygen atom or a group selected from NR7 and CHR8, wherein R7 and R8 are as defined in the description, Z represents a nitrogen atom or a CH group, n represents 1 or 2, Ak represents an alkylene chain, Ar represents an aryl or heteroaryl group, its optical isomers, and addition salts thereof with a pharmaceutically acceptable acid. Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK1 antagonist.Type: ApplicationFiled: November 10, 2008Publication date: March 19, 2009Applicant: LES LABORATOIRES SERVIERInventors: Jean-Louis Peglion, Aimee Dessinges, Bertrand Goument, Mark Millan, Clotilde Mannoury La Cour
-
Patent number: 7470683Abstract: Compounds of formula I, of trans relative configuration: wherein: X represents an oxygen atom or an NR2 group, Y represents a group selected from —CH2—, —(CH2)2— and —CH?CH—, R1 and R2, which may be the same or different, each represents a hydrogen atom or a group selected from alkyl, cycloalkyl and cycloalkylalkyl, in racemic form or in the form of optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid, and hydrates thereof. Medicinal products containing the same which are useful in the treatment of disorders of the central nervous system that involve the dopaminergic system.Type: GrantFiled: September 25, 2007Date of Patent: December 30, 2008Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Christophe Poitevin, Mark Millan, Mauricette Brocco
-
Patent number: 7465733Abstract: A compound selected from those of formula (I): wherein: R1, R2, R3 and R4, which may be the same or different, each represent an atom or group selected from hydrogen, halogen, alkyl, alkoxy, phenyl and cyano, X represents a bond, an oxygen atom or a group selected from —(CH2)m—, —OCH2— and —NR5—, wherein m represents 1 or 2, and R5 is as defined in the description, Y represents an oxygen atom or a group selected from NR7 and CHR8, wherein R7 and R8 are as defined in the description, Z represents a nitrogen atom or a CH group, n represents 1 or 2, Ak represents an alkylene chain, Ar represents an aryl or heteroaryl group, its optical isomers, and addition salts thereof with a pharmaceutically acceptable acid. Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK1 antagonist.Type: GrantFiled: March 31, 2006Date of Patent: December 16, 2008Assignee: Les Laboratoires ServierInventors: Jean-Louis Peglion, Aimée Dessinges, Bertrand Goument, Mark Millan, Clotilde Mannoury La Cour
-
Patent number: 7462741Abstract: A compound selected from those of formula (I): Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.Type: GrantFiled: June 28, 2007Date of Patent: December 9, 2008Assignee: Les Laboratoires ServierInventors: Said Yous, Basile Peres, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
-
Patent number: 7442692Abstract: A compound selected from those of formula (I): wherein: R3 represents a hydrogen atom, and R1 and R2 together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, or R1 represents a hydrogen atom, and R2 and R3 together with the carbon atoms carrying them form a benzene, naphthalene or quinoline ring structure, each of the ring structures being optionally substituted, n represents 1 or 2, —X— represents a group selected from —(CH2)m—O-Ak-, —(CH2)m—NR4-Ak-, —(CO)—NR4-Ak- and —(CH2)m—NR4-(CO)—, m represents an integer between 1 and 6 inclusive, Ak represents an optionally substituted alkylene chain, and R4 represents a hydrogen atom or an alkyl group, Ar represents an aryl or heteroaryl group, its enantiomers, diasteroisomers, and addition salts thereof with a pharmaceutically acceptable acid.Type: GrantFiled: March 29, 2006Date of Patent: October 28, 2008Assignee: Les Laboratoires ServierInventors: Guillaume De Nanteuil, Bernard Portevin, Philippe Gloanec, Mark Millan, Jean-Claude Ortuno, Clotilde Mannoury La Cour, Alain Gobert
-
Patent number: 7435850Abstract: A compound selected from those of formula (I): Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.Type: GrantFiled: June 29, 2007Date of Patent: October 14, 2008Assignee: Les Laboratoires ServierInventors: Said Yous, Basile Peres, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
-
Publication number: 20080076765Abstract: Compounds of formula I, of trans relative configuration: wherein: X represents an oxygen atom or an NR2 group, Y represents a group selected from —CH2—, —(CH2)2— and —CH?CH—, R1 and R2, which may be the same or different, each represents a hydrogen atom or a group selected from alkyl, cycloalkyl and cycloalkylalkyl, in racemic form or in the form of optical isomers, and also addition salts thereof with a pharmaceutically acceptable acid, and hydrates thereof. Medicinal products containing the same which are useful in the treatment of disorders of the central nervous system that involve the dopaminergic system.Type: ApplicationFiled: September 25, 2007Publication date: March 27, 2008Applicant: LES LABORATOIRES SERVIERInventors: Jean-Louis Peglion, Christophe Poitevin, Mark Millan, Mauricette Brocco
-
Publication number: 20080004350Abstract: A compound selected from those of formula (I): Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.Type: ApplicationFiled: June 29, 2007Publication date: January 3, 2008Applicant: LES LABORATOIRES SERVIERInventors: Said Yous, Basile Peres, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
-
Publication number: 20080004349Abstract: A compound selected from those of formula (I): Medicinal products containing the same which are useful in the treatment of disorders of the melatoninergic system.Type: ApplicationFiled: June 28, 2007Publication date: January 3, 2008Applicant: LES LABORATOIRES SERVIERInventors: Said Yous, Basile Peres, Ahmed Sabaouni, Pascal Berthelot, Michael Spedding, Philippe Delagrange, Daniel-Henri Caignard, Mark Millan
-
Publication number: 20070238792Abstract: The present invention relates to the use of agomelatine, or N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide, in obtaining medicaments intended for the treatment of Generalized Anxiety Disorder.Type: ApplicationFiled: April 4, 2007Publication date: October 11, 2007Applicant: LES LABORATOIRES SERVIERInventors: Bruno Delalleau, Agnes Fabiano, Mark Millan, Elisabeth Mocaer
-
Publication number: 20060229318Abstract: A compound selected from those of formula (I): wherein: R1, R2, R3 and R4, which may be the same or different, each represent an atom or group selected from hydrogen, halogen, alkyl, alkoxy, phenyl and cyano, X represents a bond, an oxygen atom or a group selected from —(CH2)m—, —OCH2— and —NR5—, wherein m represents 1 or 2, and R5 is as defined in the description, Y represents an oxygen atom or a group selected from NR7 and CHR8, wherein R7 and R8 are as defined in the description, Z represents a nitrogen atom or a CH group, n represents 1 or 2, Ak represents an alkylene chain, Ar represents an aryl or heteroaryl group, its optical isomers, and addition salts thereof with a pharmaceutically acceptable acid. Medical products containing the same which are useful in the treatment of conditions requiring a serotonin reuptake inhibitor and/or NK1 antagonist.Type: ApplicationFiled: March 31, 2006Publication date: October 12, 2006Inventors: Jean-Louis Peglion, Aimee Dessinges, Bertrand Goument, Mark Millan, Clotilde La Cour